Trial Profile
A Phase II Study of Dasatinib (Sprycel) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults ≥ 18 Years With Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Alemtuzumab; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Etoposide phosphate; Filgrastim; Fludarabine; Folinic acid; Folinic acid; Melphalan; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegfilgrastim; Tacrolimus; Tacrolimus; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 03 Aug 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2019 Planned End Date changed from 1 Feb 2018 to 31 Oct 2024.
- 04 Dec 2018 Results presented at the 60th Annual Meeting and Exposition of the American Society of Hematology